Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2020

Open Access 01-12-2020 | Idiopathic Pulmonary Fibrosis | Research

Determinants of health-related quality of life decline in interstitial lung disease

Authors: Phillen Nozibuyiso Maqhuzu, Boglarka L. Szentes, Michael Kreuter, Thomas Bahmer, Nicolas Kahn, Martin Claussen, Rolf Holle, Larissa Schwarzkopf

Published in: Health and Quality of Life Outcomes | Issue 1/2020

Login to get access

Abstract

Background

Health-related quality of life (HRQL) in interstitial lung disease (ILD) patients is impaired. We aimed to identify baseline predictors for HRQL decline within a 12-month observation period.

Methods

We analyzed 194 ILD patients from two German ILD-centers in the observational HILDA study. We employed the disease-specific King’s Brief Interstitial Lung Disease questionnaire (K-BILD) with the subdomains ‘psychological impact’, ‘chest symptoms’ and ‘breathlessness and activities’, and the generic EQ-5D Visual Analog Scale (VAS). We evaluated how many patients experienced a clinically meaningful decline in HRQL. Subsequently, we investigated medical and sociodemographic factors as potential predictors of HRQL deterioration.

Results

Within the study population (34.0% male, Ø age 61.7) mean HRQL scores hardly changed between baseline and follow up (K-BILD: 52.8 vs. 52.5 | VAS: 60.0 vs. 57.3). On the intra-individual level, 30.4% (n = 59) experienced a clinically relevant deterioration in K-BILD total score and 35.4% (n = 68) in VAS. Lower baseline forced vital capacity (FVC) % predicted determined HRQL decline in K-BILD total score (ß-coefficient: − 0.02, p = 0.007), VAS (ß-coefficient: − 0.03, p < 0.0001), and in the subdomain ‘psychological impact’ (ß-coefficient: − 0.02, p = 0.014). Lower baseline diffusing capacity of carbon monoxide (DLCO) % predicted determined deterioration in ‘breathlessness and activities’ (ß-coefficient: − 0.04, p = 0.003) and ‘chest symptoms’ (ß-coefficient: − 0.04, p = 0.002). Additionally, increasing age predicted decline in ‘psychological impact’ (ß-coefficient: 0.06, p < 0.007).

Conclusion

Around a third of ILD patients experienced a clinically relevant HRQL deterioration in a 12-month period, which was associated with baseline lung function values in all K-BILD domains. As lung function values are time-dependent variables with possible improvements, in contrast to age and ILD subtype, it, thus, seems important to improve lung function and prevent its decline in order to maintain HRQL on the possibly highest level.
Appendix
Available only for authorised users
Literature
1.
go back to reference Disayabutr S, Calfee CS, Collard HR, Wolters PJ. Interstitial lung diseases in the hospitalized patient. BMC Med. 2015;13:245.CrossRef Disayabutr S, Calfee CS, Collard HR, Wolters PJ. Interstitial lung diseases in the hospitalized patient. BMC Med. 2015;13:245.CrossRef
2.
go back to reference Kalchiem-Dekel O, Galvin J, Burke A, Atamas S, Todd N. Interstitial lung disease and pulmonary fibrosis: a practical approach for general medicine physicians with focus on the medical history. J Clin Med. 2018;7:476.CrossRef Kalchiem-Dekel O, Galvin J, Burke A, Atamas S, Todd N. Interstitial lung disease and pulmonary fibrosis: a practical approach for general medicine physicians with focus on the medical history. J Clin Med. 2018;7:476.CrossRef
3.
go back to reference Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M, et al. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–71.CrossRef Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M, et al. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–71.CrossRef
4.
go back to reference Meyer KC. Diagnosis and management of interstitial lung disease. Transl Respir Med. 2014;2:4. CrossRef Meyer KC. Diagnosis and management of interstitial lung disease. Transl Respir Med. 2014;2:4. CrossRef
5.
go back to reference Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, et al. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J. 2016;48:843–51. CrossRef Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, et al. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J. 2016;48:843–51. CrossRef
6.
go back to reference Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials. Respir Med. 2016;113:74–9. CrossRef Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials. Respir Med. 2016;113:74–9. CrossRef
7.
go back to reference Szende Á, Leidy NK, Revicki D. Health-related quality of life and other patient-reported outcomes in the European centralized drug regulatory process: a review of guidance documents and performed authorizations of medicinal products 1995 to 2003. Value Heal. 2005;8:534–48. CrossRef Szende Á, Leidy NK, Revicki D. Health-related quality of life and other patient-reported outcomes in the European centralized drug regulatory process: a review of guidance documents and performed authorizations of medicinal products 1995 to 2003. Value Heal. 2005;8:534–48. CrossRef
8.
go back to reference Theofilou P. Theoretical contributions quality of life: definition and measurement. Eur J Psychol. 2013;9:150–62. CrossRef Theofilou P. Theoretical contributions quality of life: definition and measurement. Eur J Psychol. 2013;9:150–62. CrossRef
9.
go back to reference Spitzer WO. State of science 1986: quality of life and functional status as target variables for research. J Chronic Dis. 1987;40:465–71. CrossRef Spitzer WO. State of science 1986: quality of life and functional status as target variables for research. J Chronic Dis. 1987;40:465–71. CrossRef
10.
go back to reference Swigris JJ, Kuschner WG, Jacobs SS, Wilson SR, Gould MK. Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax. 2005;60:588–94. CrossRef Swigris JJ, Kuschner WG, Jacobs SS, Wilson SR, Gould MK. Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax. 2005;60:588–94. CrossRef
11.
go back to reference Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res. 2017;18:139. CrossRef Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res. 2017;18:139. CrossRef
12.
go back to reference Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respir Res. 2019;20:59. CrossRef Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respir Res. 2019;20:59. CrossRef
13.
go back to reference Patel AS, Siegert RJ, Brignall K, Gordon P, Steer S, Desai SR, et al. The development and validation of the King’s Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax. 2012;67:804–10. CrossRef Patel AS, Siegert RJ, Brignall K, Gordon P, Steer S, Desai SR, et al. The development and validation of the King’s Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax. 2012;67:804–10. CrossRef
14.
go back to reference Szentes BL, Kreuter M, Bahmer T, Birring SS, Claussen M, Waelscher J, et al. Quality of life assessment in interstitial lung diseases: a comparison of the disease-specific K-BILD with the generic EQ-5D-5L. Respir Res. 2018;19:101. CrossRef Szentes BL, Kreuter M, Bahmer T, Birring SS, Claussen M, Waelscher J, et al. Quality of life assessment in interstitial lung diseases: a comparison of the disease-specific K-BILD with the generic EQ-5D-5L. Respir Res. 2018;19:101. CrossRef
15.
16.
go back to reference Sinha A, Patel AS, Siegert RJ, Bajwah S, Maher TM, Renzoni EA, et al. The King’s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference. BMJ Open Respir Res. 2019;6:e000363.CrossRef Sinha A, Patel AS, Siegert RJ, Bajwah S, Maher TM, Renzoni EA, et al. The King’s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference. BMJ Open Respir Res. 2019;6:e000363.CrossRef
17.
go back to reference Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36.CrossRef Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36.CrossRef
18.
go back to reference Nolan CM, Longworth L, Lord J, Canavan JL, Jones SE, Kon SSC, et al. The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference. Thorax. 2016;71:493–500.CrossRef Nolan CM, Longworth L, Lord J, Canavan JL, Jones SE, Kon SSC, et al. The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference. Thorax. 2016;71:493–500.CrossRef
19.
go back to reference Barstow C, Forbes D. Respiratory conditions: chronic obstructive pulmonary disease. FP Essent. 2019;486:26–32.PubMed Barstow C, Forbes D. Respiratory conditions: chronic obstructive pulmonary disease. FP Essent. 2019;486:26–32.PubMed
20.
go back to reference Forbes D, Shahan B. Respiratory conditions: interstitial lung Disease. FP Essent. 2019;486:33–44.PubMed Forbes D, Shahan B. Respiratory conditions: interstitial lung Disease. FP Essent. 2019;486:33–44.PubMed
21.
go back to reference Berry CE, Drummond MB, Han MLK, Li D, Fuller C, Limper AH, et al. Relationship between lung function impairment and health-related quality of life in COPD and interstitial lung disease. Chest. 2012;142:704–11.CrossRef Berry CE, Drummond MB, Han MLK, Li D, Fuller C, Limper AH, et al. Relationship between lung function impairment and health-related quality of life in COPD and interstitial lung disease. Chest. 2012;142:704–11.CrossRef
22.
go back to reference Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, et al. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS ONE. 2016;11:e0151425.CrossRef Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, et al. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS ONE. 2016;11:e0151425.CrossRef
23.
go back to reference Kolb M, Vašáková M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20:57.CrossRef Kolb M, Vašáková M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20:57.CrossRef
24.
go back to reference Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018;51:1–12.CrossRef Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018;51:1–12.CrossRef
25.
go back to reference Fernández Pérez ER, Daniels CE, Schroeder DR, St. Sauver J, Hartman TE, Bartholmai BJ, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis a population-based study. Chest. 2010;137:129–37.CrossRef Fernández Pérez ER, Daniels CE, Schroeder DR, St. Sauver J, Hartman TE, Bartholmai BJ, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis a population-based study. Chest. 2010;137:129–37.CrossRef
26.
go back to reference Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1–10.CrossRef Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1–10.CrossRef
27.
go back to reference Coelho AC, Knorst MM, Gazzana MB, Barreto SSM. Predictors of physical and mental health-related quality of life in patients with interstitial lung disease: a multifactorial analysis. J Bras Pneumol. 2010;36:562–70.CrossRef Coelho AC, Knorst MM, Gazzana MB, Barreto SSM. Predictors of physical and mental health-related quality of life in patients with interstitial lung disease: a multifactorial analysis. J Bras Pneumol. 2010;36:562–70.CrossRef
28.
go back to reference Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, Collard HR. Depression and Functional status are strongly associated with dyspnea in interstitial lung disease. Chest. 2011;139:609–16.CrossRef Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, Collard HR. Depression and Functional status are strongly associated with dyspnea in interstitial lung disease. Chest. 2011;139:609–16.CrossRef
29.
go back to reference Antoniou KM, Margaritopoulos GA, Tomassetti S, Bonella F, Costabel U, Poletti V. Interstitial lung disease. Eur Respir Rev. 2014;23:40–54.CrossRef Antoniou KM, Margaritopoulos GA, Tomassetti S, Bonella F, Costabel U, Poletti V. Interstitial lung disease. Eur Respir Rev. 2014;23:40–54.CrossRef
30.
go back to reference Ryerson CJ, Arean PA, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, et al. Depression is a common and chronic comorbidity in patients with interstitial lung disease. Respirology. 2012;17:525–32.CrossRef Ryerson CJ, Arean PA, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, et al. Depression is a common and chronic comorbidity in patients with interstitial lung disease. Respirology. 2012;17:525–32.CrossRef
32.
go back to reference Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–40. www.atsjournals.org. Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–40. www.​atsjournals.​org.
33.
go back to reference Aldhaheri S, Moran-Mendoza O, Mccarthy L. Clinical impact of an interstitial lung disease Nurse on patients with idiopathic pulmonary fibrosis. Eur Respir J. 2018;52(62Suppl):PA5240. Aldhaheri S, Moran-Mendoza O, Mccarthy L. Clinical impact of an interstitial lung disease Nurse on patients with idiopathic pulmonary fibrosis. Eur Respir J. 2018;52(62Suppl):PA5240.
34.
go back to reference Margaritopoulos GA, Antoniou KM, Wells AU. Comorbidities in interstitial lung diseases. Eur Respir Rev. 2017;26:160027.CrossRef Margaritopoulos GA, Antoniou KM, Wells AU. Comorbidities in interstitial lung diseases. Eur Respir Rev. 2017;26:160027.CrossRef
35.
go back to reference King C, Nathan SD. Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases. Curr Opin Pulm Med. 2013;19:466–73.CrossRef King C, Nathan SD. Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases. Curr Opin Pulm Med. 2013;19:466–73.CrossRef
36.
go back to reference Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan L, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003;58:339–43.CrossRef Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan L, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003;58:339–43.CrossRef
37.
go back to reference Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2014;2014(10):CD006322.;. Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2014;2014(10):CD006322.;.
38.
go back to reference Pugashetti J, Graham J, Boctor N, Mendez C, Foster E, Juarez M, et al. Weight loss as a predictor of mortality in patients with interstitial lung disease. Eur Respir J. 2018;52(3):1801289.CrossRef Pugashetti J, Graham J, Boctor N, Mendez C, Foster E, Juarez M, et al. Weight loss as a predictor of mortality in patients with interstitial lung disease. Eur Respir J. 2018;52(3):1801289.CrossRef
39.
go back to reference Kondoh Y, Taniguchi H, Ebina M, Azuma A, Ogura T, Taguchi Y, et al. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis-extended analysis of pirfenidone trial in Japan. Respir Investig. 2015;53:271–8.CrossRef Kondoh Y, Taniguchi H, Ebina M, Azuma A, Ogura T, Taguchi Y, et al. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis-extended analysis of pirfenidone trial in Japan. Respir Investig. 2015;53:271–8.CrossRef
40.
go back to reference Hyldgaard C, Hilberg O, Muller A, Bendstrup E. A cohort study of interstitial lung diseases in central Denmark. Respir Med. 2014;108:793–9. CrossRef Hyldgaard C, Hilberg O, Muller A, Bendstrup E. A cohort study of interstitial lung diseases in central Denmark. Respir Med. 2014;108:793–9. CrossRef
41.
go back to reference Guler Sabina A, Pascal Z, Sabina B, Alexander P, Thomas G, Manuela FC. Idiopathic pulmonary fibrosis in a Swiss interstitial lung disease reference centre. Swiss Med Wkly. 2018;148:14577. Guler Sabina A, Pascal Z, Sabina B, Alexander P, Thomas G, Manuela FC. Idiopathic pulmonary fibrosis in a Swiss interstitial lung disease reference centre. Swiss Med Wkly. 2018;148:14577.
Metadata
Title
Determinants of health-related quality of life decline in interstitial lung disease
Authors
Phillen Nozibuyiso Maqhuzu
Boglarka L. Szentes
Michael Kreuter
Thomas Bahmer
Nicolas Kahn
Martin Claussen
Rolf Holle
Larissa Schwarzkopf
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2020
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-020-01570-2

Other articles of this Issue 1/2020

Health and Quality of Life Outcomes 1/2020 Go to the issue